This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Jentadueto
  • /
  • BI 1356 (Linagliptin) in Combination With Metformi...
Clinical trial

BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

Read time: 1 mins
Last updated:1st Feb 2008

The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in patients with type 2 diabetes mellitus with insufficient glycaemic control.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg) Administered Orally Once Daily Over 24 Weeks, With an Open-label Extension to One Year (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With a Sulphonylurea
Enrollment: 1058
Study Start Date: February 2008
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
linagliptin 5 mg
- Placebo Comparator: placebo

Category Value
Study start date 2008-02-01

View full details